Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.63 |
| ▸ | ESRRG | P62508 | 16/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.54 |
| ▸ | ESRRB | O95718 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5725990 | 1.00 | ESR1 (0.63) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL7108569 | 1.00 | ESR1 (0.63) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL7108560 | 1.00 | ESR1 (0.63) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8367727 | 0.97 | ESR1 (0.60) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8367728 | 0.97 | ESR1 (0.60) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8362758 | 0.96 | ESR1 (0.58) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8362756 | 0.96 | ESR1 (0.58) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL8368223 | 0.96 | ESR1 (0.58) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL5726815 | 0.94 | ESRRG (0.57) | ESR1ESR2ESRRGCYP19A1ESRRB | |
| SCHEMBL5727016 | 0.94 | ESRRG (0.57) | ESR1ESR2ESRRGCYP19A1ESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975832-B2 | Process for the preparation of ospemifene and fispemifene | OLON S.P.A. (IT) | 2018-05-22 | — | — | US | disclosed |
| US-9975832-B2 | Process for the preparation of ospemifene and fispemifene | OLON S.P.A. (IT) | 2018-05-22 | — | — | US | disclosed |
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK LIFE SCIENCES LIMITED (IN) | 2018-01-25 | — | — | US | disclosed |
| US-20170342007-A1 | PROCESS FOR THE PREPARATION OF OSPEMIFENE AND FISPEMIFENE | OLON S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170342007-A1 | PROCESS FOR THE PREPARATION OF OSPEMIFENE AND FISPEMIFENE | OLON S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| WO-2016110805-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016110805-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016108172-A1 | PROCESS FOR THE PREPARATION OF OSPEMIFENE AND FISPEMIFENE | OLON S.P.A. (IT) | 2016-07-07 | — | — | WO | disclosed |
| EP-0900077-B1 | Use of a toremifene metabolite for lowering serum cholesterol level. | ORION CORP (FI) | 2002-02-06 | — | — | EP | disclosed |
| US-6037379-A | Serum cholesterol lowering agent | ORION CORPORATION (FI) | 2000-03-14 | — | — | US | disclosed |
| EP-0779808-B1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION YHTYMAE OY (FI) | 1999-08-18 | — | — | EP | disclosed |
| EP-0900077-A1 | SERUM CHOLESTEROL LOWERING AGENT | ORION-YHTYMÄ OY (FI) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997032574-A1 | SERUM CHOLESTEROL LOWERING AGENT | Orion-Yhtymä Oy (FI) | 1997-09-12 | — | — | WO | disclosed |
| EP-0779808-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION-YHTYMÄ OY (FI) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007402-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | Orion-Yhtymä Oy (FI) | 1996-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022674-A1 | PROCESS FOR PREPARATION OF OSPEMIFENE | CYP3A4, MME, CYP4B1 | ESR1 92/4885ESR2 67/4885ESRRG 623/4885 |
| US-20170342007-A1 | PROCESS FOR THE PREPARATION OF OSPEMIFENE AND FISPEMIFENE | CYP2F1, FOXO1, NFE2L2 | ESR1 151/4885ESR2 133/4885ESRRG 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.